Quality Systems

Articles

Designated as a "pharmerging market," Brazil is revamping its pricing models.

Report From: Brazil

Patent infringement claims and a lack of clear global trade distribution routes may be unraveling the country's generic-drug export industry.

Report From India: A new patent battleground has formed over India's drug shipments through the European Union.

With the economy down and multinational firms capitalizing on patents in developing countries, India's R&D sector still has a long way to grow.

Report From: India

Jane Wan is a freelance writer based in Singapore.

Although its domestic market is on the rise, Pakistan's market conditions have not proved welcoming enough to keep foreign investors.

Report from: Pakistan

A. Nair is a freelance writer based in Mumbai, India.

While the world pulls itself out from one of the worst crises in decades, Indian pharmaceutical companies are trying to capitalize on falling company prices by increasing their takeovers.

The Indian government may soon monopolize its pharmaceutical industry to cut costs and improve healthcare, but the move is sounding off alarm bells with the companies whose drug products are under review.

Report from: India

Differential pricing is making more than just an appearance in Asia's pharma market these days.

The US Pharmacopeial Conventional added to its international sites with the official opening of its facility in Sao Paulo, Brazil.

USP Opens Site in Brazil

With rising drug deveopment costs and burdensome clinical trials, Indian-based firms are transferring their research departments to other entities in hopes of saving cash, mitigating risk, and ultimately, buying back the rewards.

A. Nair discusses patent disputes in India.

Regulatory/GMP Compliance, Emerging Markets